$187,911.02 ownership Payment -- Pfizer Inc to Dr. Charles Baker

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Pfizer Inc made a $187.9K ownership payment to Charles Baker, a Oncology specialist in City, WI. The payment was associated with Ibrance. This record details a significant ownership interest payment of $187,911.02 from Pfizer Inc. to Dr. Charles Baker, an Oncologist. The payment is associated with the drug Ibrance, indicating a potential financial tie to a specific pharmaceutical product. The payment date is set for January 15, 2026, which is in the future, suggesting a planned or ongoing arrangement.

Patient Guidance: What This Payment Means for You

If you are a patient receiving treatment with Ibrance, be aware that your oncologist may have an ownership interest in the company that manufactures it. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Ownership interests in pharmaceutical companies are common in specialties like Oncology, where physicians often have deep knowledge of and investment in specific treatments.

Regulatory Context: Sunshine Act Requirements

This disclosure falls under the Physician Payments Sunshine Act, requiring transparency in financial relationships between drug manufacturers and healthcare providers.

Related Topics

This payment is related to the following healthcare transparency topics:

• ownership-interest
• pharmaceutical-payment
• oncology
• ibrance
• pfizer-inc
• physician-payment

Understanding ownership Payments

Ownership and investment interest payments represent dividends, returns, or other financial benefits from physician ownership stakes in pharmaceutical or medical device companies. These relationships represent the most direct form of financial interest and are subject to the strictest reporting requirements under the Sunshine Act.

Frequently Asked Questions About This Payment

What was this $187.9K payment for?

This was a ownership payment of $187.9K from Pfizer Inc to Charles Baker, categorized as "Ownership or Investment Interest". It was associated with Ibrance. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Charles Baker accept pharmaceutical money?

Yes, Charles Baker received this $187.9K payment from Pfizer Inc. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Charles Baker's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this ownership payment?

A ownership payment of $187.9K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Oncology?

To compare this payment against Oncology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Oncology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Charles Baker's relationship with Pfizer Inc?

The payment amount is substantial, exceeding typical consulting or speaking fees. This $187.9K ownership payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Oncology?

The payment type is 'ownership interest,' which is distinct from direct payments for services.

What should patients do after learning about this payment?

If you are a patient receiving treatment with Ibrance, be aware that your oncologist may have an ownership interest in the company that manufactures it.

What else should I know about this ownership payment?

The specific drug 'Ibrance' is mentioned, linking the ownership interest to a particular product.

Related Reports

• View Dr. Charles Baker's full payment report
• Pfizer Inc full spending report
• Browse all Oncology payments
• Browse all payments in Wisconsin
• Search for other payments